Protagonist Therapeutics shares are trading higher after it was announced the company will join the S&P SmallCap 600.
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics shares are trading higher after it was announced the company will join the S&P SmallCap 600.
June 28, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics shares are trading higher following the announcement that the company will join the S&P SmallCap 600.
Inclusion in the S&P SmallCap 600 typically leads to increased visibility and demand from index funds and investors, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100